---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022592"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:00:16.126136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M

## Summary
- Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).
- Sold 6,595 LALs (+234% YoY); gross margin improved to 42.5% vs 23.2% in Q3 2021.
- Raised FY2022 revenue guidance to $47-48M (from $44-46M); gross margin guidance raised to 41-43%.
- Net loss of $(16.8)M or $(0.61)/share vs $(12.7)M or $(0.68)/share in Q3 2021.
- Cash & investments $112.8M; long-term debt $40.0M; operating expense guidance lowered.

## SEC filing metadata
- accession: 0000950170-22-022592
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/0000950170-22-022592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/rxst-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022592
- JSON: https://secwatch.observer/filing/0000950170-22-022592.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022592.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported three and nine months ended September 30, 2022 results: revenue $12.6 million, net income $(16.8) million, EPS $(0.61) per basic and diluted share. Guidance raised.
  - Period: three and nine months ended September 30, 2022
  - Revenue: $12.6 million
  - Net income: $(16.8) million
  - EPS: $(0.61) per basic and diluted share
  - Guidance: raised
  - Result: reported results
  source text: cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: • Delivered third quarter 2022 revenue of $12.6 million, an increase of 118% compared to the third quarter of 2021, reflecting: • The sale of 49 Light Delivery Devices (LDDTMs), representing a 58% unit increase from the third quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/0000950170-22-022592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.